Mechanisms of cardiovascular protection of non-insulin antidiabetic medications

Mechanisms of cardiovascular protection of non-insulin antidiabetic medications

Patients with type 2 diabetes mellitus die most frequently from cardiovascular disease (CVD). Metabolic control is a cornerstone of both primary and secondary prevention of CVD: its important is two-fold since the normalization of HbA1c not only counteracts the onset, and the progression of microvas...

Full description

Bibliographic Details
Main Author:	Angelo Avogaro
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2018-12-01
Series:	Сахарный диабет
Subjects:	cardiovascular disease type 2 diabetes mellitus complications of diabetes mellitus dipeptidyl peptidase iv inhibitors glucagon-like peptide 1 sodium glucose transporter 2
Online Access:	https://dia-endojournals.ru/dia/article/viewFile/9816/pdf

Similar Items

Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke
by: Chang Ho Ahn, et al.
Published: (2019-05-01)

Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
by: Angelo Maria Patti, et al.
Published: (2020-03-01)

Uptake of new antidiabetic medicines in 11 European countries
by: Nika Mardetko, et al.
Published: (2021-06-01)

Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta‐analysis
by: Sanaz Kamalinia, et al.
Published: (2020-01-01)

The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy
by: Keshav Gopal, et al.
Published: (2020-12-01)

EFFICIENCY AND SAFETY OF THE ORAL HYPOGLYCAEMIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASES
by: E. I. Makeeva, et al.
Published: (2016-02-01)

Nuevas terapias en diabetes: más allá de la insulina inyectable y de los antidiabéticos orales New therapies for diabetes: beyond injectable insulin and oral antidiabetics
by: John Edwin Feliciano Alfonso, et al.
Published: (2008-10-01)

Effects of Incretin-Based Therapies on Diabetic Microvascular Complications
by: Yu Mi Kang, et al.
Published: (2017-09-01)

Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double‐blind, placebo‐controlled study
by: Linong Ji, et al.
Published: (2021-04-01)

The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes
by: Clara García-Carro, et al.
Published: (2019-06-01)

Adjunctive therapy for glucose control in patients with type 1 diabetes
by: Harris K, et al.
Published: (2018-04-01)

Exercise and the dipeptidyl‐peptidase IV inhibitor sitagliptin do not improve beta‐cell function and glucose homeostasis in long‐lasting type 1 diabetes—A randomised open‐label study
by: Eleonora Seelig, et al.
Published: (2019-07-01)

Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease
by: Sook Jung Lee, et al.
Published: (2019-12-01)

Las incretinas como nueva opción terapéutica en la diabetes mellitus tipo 2
by: Félix Andrés Reyes Sanamé, et al.

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
by: Julio Rosenstock, et al.
Published: (2018-03-01)

A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin
by: Hiroshi Nomoto, et al.
Published: (2017-07-01)

Discovery of Food-Derived Dipeptidyl Peptidase IV Inhibitory Peptides: A Review
by: Rui Liu, et al.
Published: (2019-01-01)

An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass
by: Suk Chon, et al.
Published: (2016-04-01)

Functional foods with dipeptidyl peptidase‐4 inhibitory potential and management of type 2 diabetes: A review
by: Mutiu Kazeem, et al.
Published: (2021-06-01)

Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis
by: Elvira D’Andrea, et al.
Published: (2020-09-01)

A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus
by: Sae Jeong Yang, et al.
Published: (2021-07-01)

Impact of sitagliptin combination therapy and hypoglycemia in Japanese patients with type 2 diabetes: a multi-center retrospective observational cohort study
by: Tomoyuki Saito, et al.
Published: (2020-06-01)

Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study
by: Nam Hoon Kim, et al.
Published: (2017-06-01)

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus
by: Sung-Ho Kim, et al.
Published: (2016-09-01)

Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies
by: Dimitrios Patoulias, et al.
Published: (2021-08-01)

The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors
by: Vladimer Darsalia, et al.
Published: (2018-02-01)

Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series
by: Lajthia E, et al.
Published: (2019-12-01)

Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
by: Awadhesh Kumar Singh
Published: (2014-01-01)

Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus
by: Geert Jan Biessels, et al.
Published: (2018-01-01)

Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier
by: Dandan Zhao, et al.
Published: (2018-03-01)

Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale
by: Yassin SA, et al.
Published: (2017-03-01)

Glucagon-like peptide 1 and dysglycemia: Conflict in incretin science
by: Awadhesh Kumar Singh
Published: (2015-01-01)

Efeito do inibidor da DPP-IV sobre glicemia, glucagon, insulina, peptídeo C, GLP-1 e ácidos graxos livres após dietas isocalóricas de diferentes composições nutricionais em pacientes diabéticos tipo 2 virgens de tratamentos
by: Cristina da Silva Schreiber de Oliveira
Published: (2013)

Efeito do inibidor da DPP-IV sobre glicemia, glucagon, insulina, peptídeo C, GLP-1 e ácidos graxos livres após dietas isocalóricas de diferentes composições nutricionais em pacientes diabéticos tipo 2 virgens de tratamentos
by: Oliveira, Cristina da Silva Schreiber de
Published: (2013)

Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis
by: Dan Liu, et al.
Published: (2019-03-01)

New Drugs for Type 2 Diabetes: New Hopes and New Concerns About the Skeleton
by: Zehra Berberoglu
Published: (2016-10-01)

Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies
by: Jang Won Son, et al.
Published: (2015-10-01)

Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
by: Yoshio Sumida, et al.
Published: (2020-03-01)

Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes
by: Anand-Krishna Singh, et al.
Published: (2021-06-01)

Glucagon like Peptide-1(GLP-1) a Novel Therapeutic Strategy in Non-Alcoholic Fatty Liver Disease (NAFLD)
by: Ebrahim Abbasi Oshaghi
Published: (2017-12-01)